Trials / Completed
CompletedNCT03439917
Effects of Carnitine Supplementation on Liver and Muscle
Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- University of Nottingham · Academic / Other
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves metabolism in individuals who have a high concentration of fat within their liver. Participants will be given either Carnitine or placebo, together with a meal replacement milkshake twice daily for 6 months.
Detailed description
NAFLD occurs when too much fat accumulates in liver tissue. This can, over time, cause inflammation and scarring of the liver, eventually leading to chronic liver disease and cirrhosis. It is strongly associated with diabetes and obesity, both of which are endemic in Western societies. Carnitine enables cells in the body to use fat as a fuel, and recent studies have suggested that carnitine supplementation may reduce liver triglyceride content. Muscle and liver are the major sites in the body which coordinate glucose and fat metabolism. As well as assessing the effect of carnitine supplementation on liver fat, its effect on metabolic processes within these tissues will also be measured
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | L-Carnitine tartrate | 2g L-Carnitine tartrate as a powder consumed twice a day |
| DIETARY_SUPPLEMENT | Meal Replacement Drink | 325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day |
| DIETARY_SUPPLEMENT | Maltodextrin | 2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day |
Timeline
- Start date
- 2018-04-02
- Primary completion
- 2020-08-30
- Completion
- 2021-11-01
- First posted
- 2018-02-20
- Last updated
- 2021-11-30
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03439917. Inclusion in this directory is not an endorsement.